The new list of vital and essential drugs (VED) to enter into force in 2012
By decision of the Ministry of Health and Social Development of the list of drugs submitted for public discussion, all comments on the document adopted at the site office.
As reported on the website of the Ministry for drugs included in the VED list, in 2010 introduced state regulation of prices. The draft list is reviewed annually and is put up for public discussion.
Its findings on the new project during the month of VED can send as expert organizations and individuals.
The updated version of the list includes 563 Medications . Among them, 94 are produced only in Russia, 202 names produced by foreign manufacturers, and the production of 267 kinds of medicines made both Russian and foreign pharmaceutical companies.
See A new list of vital and essential drugs (VED) (.doc, 885 KB)
According to the Health Ministry press service, the document excluded from the new guidance on specific dosage forms.
"In order to avoid the conditions for the prevention, restriction or elimination of competition in the pharmaceutical market of the Russian Federation from the draft List of VED in 2012 excluded references to specific dosage forms, while included in the project preparations corresponding state register of medicines for medical use," - said in a official statement. That is, the list is no indication on the shape of the drug - this syrups, sprays, tablets or capsules.
In addition, the list of essential drugs used WHO recommended international anatomical and therapeutic and chemical classification of medicines, since the drafting of the document was taken as a basis for a similar list of the World Health Organization (WHO). Similar lists have already been approved in more than 160 countries. Typically, these lists of vital and essential drugs (VED) are those products that meet the needs of the health system with regard to their efficiency, safety, affordability.
24 products
The new list of medicines developed by the Commission, which included Head Specialist Health Ministry. The Commission included in the list of 24 products that were not available in previous versions of the document. Among them:
- Anti-microbial and anti-TB drugs used in the treatment of complicated forms tukberkuleza, including multidrug-resistant (gatifloxacin, lomefloxacin, sparfloxacin, moxifloxacin, Terizidone)
- Hemostatic agent used in the care of patients with hemophilia inhibitor (Antiingibitorny coagulant complex)
- Antianemic drug used to treat anemia in adults and children c chronic renal failure, and patients with non-myeloid have malignancies receiving chemotherapy (Darbepoetin alfa)
- Antihypertensive drug used for controlled hypotension, including during surgery and in the treatment of hypertensive crises, and severe refractory hypertension (Urapidil)
- Antifungal drugs (Caspofungin) used for the treatment of fungal infections (Micafungin) used for the prevention and treatment of candidiasis, including patients after allogeneic bone marrow transplantation
- Antimetabolite anticancer drug used for the treatment of small cell lung cancer, as well as in the treatment of pleural mesothelioma
Pemetrexed.
- Antimetabolite agent, intended for the treatment of T-cell acute lymphocytic leukemia and lymphomas (Nelarabin)
- Anticancer agent appointed for metastatic colorectal cancer, and squamous cell carcinoma of the head and neck (Cetuximab)
- An antineoplastic drug used to treat lung cancer (Gefitinib)
- Used in hematology anticancer drugs in the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia with Philadelphia chromosome positive (Dasatinib, Nilotinib)
- An anticancer drug used for the treatment of metastatic renal cell carcinoma, and primary liver cancer (Sorafenib)
- Antineoplastic agent used for the treatment of renal cell carcinoma and gastrointestinal stromal tumors (Sunitinib)
- Immunomodulating agent intended for the treatment and prevention of recurrence of bladder cancer (cancer vaccine for the treatment of bladder BCG)
- Immunostimulant drug used for the prevention and treatment of secondary immunodeficiency states, as well as for potentiation of antibacterial effects, including a comprehensive anti-TB therapy (glutamyl-cysteine-glycine disodium)
- Immunosuppressive agent used to treat patients with moderate to severe rheumatoid arthritis and juvenile idiopathic arthritis (Abatacept)
- Immunosuppressive agent used for the prevention of transplant rejection in adult heart and kidney recipients (Everolimus)
- Immunomodulatory agent with anti-angiogenic effect, used to treat patients with multiple myeloma who have received at least one line of therapy (Lenalidomide)
- Used in ophthalmology for the treatment of neovascular (wet) form of age-related macular degeneration in adults, leading to blindness (ranibizumab)
Read the draft list of vital and essential drugs (VED) for 2012 and to discuss it, please visit the Ministry of the Russian Federation.
Source
 | The prices of essential drugs will grow | |  | The Ministry of Health counted saving drugs | |  | Essential medicines will no longer be separated into syrups and pills? | |  | Essential drugs became less | |
Other news
Go back to the main page